(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 11.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 47.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.17%.
Niagen Bioscience's revenue in 2026 is $129,084,000.On average, 8 Wall Street analysts forecast NAGE's revenue for 2026 to be $10,743,728,552, with the lowest NAGE revenue forecast at $10,100,434,155, and the highest NAGE revenue forecast at $11,208,198,183. On average, 7 Wall Street analysts forecast NAGE's revenue for 2027 to be $12,533,558,717, with the lowest NAGE revenue forecast at $11,864,152,740, and the highest NAGE revenue forecast at $13,093,770,811.
In 2028, NAGE is forecast to generate $14,714,271,332 in revenue, with the lowest revenue forecast at $13,353,304,098 and the highest revenue forecast at $15,827,574,180.